Who
Robert Hershberg
Director
Company insider
Files Form 4 as: Director, Recursion Pharmaceuticals; Director, AtaiBeckley; Director, Adaptive Biotechnologies; Director, Atai Beckley; President and CEO, HilleVax; Director, Fate Therapeutics; Director, ARS Pharmaceuticals; Director, NanoString Technologies.
In numbers
- Trades disclosed
- 214
- Buys
- 0
- Sells
- 35
- Bought
- $0
- Sold
- $6.6M
- Companies
- 9
- Companies where not an officer
- 7
- First trade
- 31 Jan 2005
- Last trade
- 6 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 7 Oct 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $56K25,000 at $2.22 | filing |
| 6 Oct 2026filed 7 Oct 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $125K25,000 at $5.00 | filing |
| 6 Oct 2026filed 7 Oct 2026 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | $56K25,000 at $2.22 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —48,858 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —404,869 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —62,394 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —48,858 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —404,869 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —62,394 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —121,968 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —121,968 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Code M | $95K15,000 at $6.32 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Sold | $366K15,000 at $24.39 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Sold | $382K15,664 at $24.41 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ADPT Adaptive Biotechnologiesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ADPT Adaptive Biotechnologiesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Code M | $95K15,000 at $6.32 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ADPT Adaptive BiotechnologiesDiagnostics & Labs | SEC FORM 4 Sold | $366K15,000 at $24.39 | filing |
News
Danaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directorsprnewswire.com · 12 Oct 2026Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 11,881 Shares of Company StockADPT · dailypolitical.com · 21 Oct 2026Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Lifted to "Sell" by Wall Street ZenRXRX · dailypolitical.com · 18 Oct 2026
1 headline in the last 90 days name Robert Hershberg; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.